Oyster Point Pharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. was a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker OYST before being acquired by Viatris, with the transaction completed on January 3, 2023. The company belonged to the Health & Pharma sector and was headquartered in Princeton, New Jersey, United States. Its business model was highly focused: developing and commercializing ophthalmic therapies, primarily for dry eye disease and, more broadly, ocular surface disorders. Founded in 2015, Oyster Point began as a clinical-stage biotech and later transitioned into a commercial-stage company following FDA approval of its lead product, TYRVAYA (varenicline solution) Nasal Spray, in October 2021. That approval was the defining milestone in the company’s history. TYRVAYA was designed to increase natural tear production via a nasal spray delivery route, giving Oyster Point a differentiated mechanism of action in an otherwise crowded ophthalmology market. From an investor’s perspective, the company’s narrative was built around innovation, clinical differentiation, and the potential to address a large and underpenetrated dry eye population. The product portfolio was intentionally narrow, which is common for specialty biopharma names at this stage. TYRVAYA was the central commercial asset, while the broader R&D platform remained concentrated on ocular surface disease programs. This created both opportunity and risk: the upside came from a first-mover, differentiated product in a large addressable market; the downside was reliance on a single commercial driver, regulatory execution, and physician adoption. As a result, Oyster Point was the kind of company where clinical, commercial, and reimbursement milestones mattered disproportionately. In competitive terms, Oyster Point operated against larger ophthalmology and specialty pharma players with established commercial infrastructure. Its strategy was to compete through product differentiation rather than scale, emphasizing the novel nasal administration route and a mechanism intended to restore tear-film homeostasis. The company’s geographic footprint was mainly U.S.-centric, although it had also pursued licensing arrangements for certain international markets, including Greater China. The most important recent corporate event was the acquisition by Viatris, announced in 2022 and closed in early 2023. Under the transaction terms, Oyster Point shareholders received $11 per share in cash, plus a contingent value right tied to specified performance milestones. For current market readers, especially those looking at SEC Form 4 insider activity, the key point is that OYST no longer trades independently on NASDAQ. However, the historical business profile remains relevant for understanding the strategic rationale behind the acquisition, the company’s commercialization trajectory, and the quality of the asset that Viatris brought into its eye-care franchise.